WO2006033196A1 - 創傷被覆材 - Google Patents
創傷被覆材 Download PDFInfo
- Publication number
- WO2006033196A1 WO2006033196A1 PCT/JP2005/012698 JP2005012698W WO2006033196A1 WO 2006033196 A1 WO2006033196 A1 WO 2006033196A1 JP 2005012698 W JP2005012698 W JP 2005012698W WO 2006033196 A1 WO2006033196 A1 WO 2006033196A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silk
- wound
- wound dressing
- firing
- fired body
- Prior art date
Links
- 238000010304 firing Methods 0.000 claims abstract description 36
- 239000000463 material Substances 0.000 claims abstract description 29
- 239000011148 porous material Substances 0.000 claims abstract description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 93
- 206010052428 Wound Diseases 0.000 claims description 90
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
- 239000004744 fabric Substances 0.000 claims description 14
- 239000002759 woven fabric Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000004745 nonwoven fabric Substances 0.000 claims description 8
- 239000003357 wound healing promoting agent Substances 0.000 claims description 7
- 238000010000 carbonizing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 20
- 206010033675 panniculitis Diseases 0.000 description 14
- 210000004304 subcutaneous tissue Anatomy 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 10
- 239000000835 fiber Substances 0.000 description 8
- 206010039509 Scab Diseases 0.000 description 7
- 238000001237 Raman spectrum Methods 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 238000001354 calcination Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000037311 normal skin Effects 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000000445 field-emission scanning electron microscopy Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012764 semi-quantitative analysis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004380 ashing Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000003575 carbonaceous material Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
- D01F9/08—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of inorganic material
- D01F9/12—Carbon filaments; Apparatus specially adapted for the manufacture thereof
- D01F9/14—Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments
- D01F9/18—Carbon filaments; Apparatus specially adapted for the manufacture thereof by decomposition of organic filaments from proteins, e.g. from wool
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00246—Wound bandages in a special way pervious to air or vapours
- A61F2013/00251—Wound bandages in a special way pervious to air or vapours with macroscopic openings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00519—Plasters use for treating burn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00855—Plasters pervious to air or vapours
- A61F2013/00859—Plasters pervious to air or vapours with macroscopic openings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present invention relates to a wound dressing.
- Japanese Patent Application Laid-Open No. 11-70160 discloses a wound dressing material having a non-crystalline film strength having a crystallinity of less than 10%, which is mainly composed of phive mouth-in and sericin. In the case of this wound dressing, it has excellent properties that it is rich in flexibility, has water absorbency, and is difficult to adhere to the skin.
- Patent Document 1 Japanese Patent Laid-Open No. 11-70160
- a fired silk material obtained by firing and carbonizing a silk material other than the silk material itself has excellent antibacterial properties, and the surface of the silk fired material is subjected to activation treatment or the like.
- a silk fired body in which a large number of pores are formed it has been found that it has further excellent water absorption and is further excellent as a wound dressing material.
- the wound dressing according to the present invention is a silk fired body obtained by firing and carbonizing a silk material, and also has a silk fired body strength in which a large number of pores are formed on the surface.
- the silk fired body is preferably a silk fired body obtained by firing and carbonizing a silk material in a temperature range of 500 ° C to 1000 ° C. Further, the silk fired body contains 5 wt% to 35 wt% of nitrogen element.
- the silk fired body can be irradiated with microwaves to form pores.
- the silk fired body can be used in the form of a woven fabric, a knitted fabric, a nonwoven fabric or a yarn.
- These woven, knitted and non-woven fabrics can be used by adding a wound healing agent.
- the silk fired body can be crushed and used as a wound healing agent.
- the wound dressing according to the present invention since it is fired at a low temperature, it retains the inherent flexibility of the silk material, and also has excellent antibacterial properties, excellent water absorption and moisture retention, and thus has excellent wound reproducibility. In addition, it can eliminate the damage or peeling of the regenerated skin.
- FIG. 1 is a Raman spectrum diagram of a fired product when coarse-grained silk is fired at a high temperature of 2000 ° C.
- FIG. 2 Raman spectrum of fired product when coarse silk is fired at a high temperature of 700 ° C.
- FIG. 3 Raman spectrum of the fired product when coarse silk is fired at a high temperature of 1000 ° C.
- FIG. 7 A photograph one day after the creation of burns and a drawing of the measurement site.
- FIG. 8 is a graph comparing the wound area ratio (%) on each measurement day to the wound area on the wound creation day.
- FIG. 9 shows a skin tissue image around the burn wound 3 days after the burn was created.
- (C-D): (A) The area around the burn wound surrounded by the square in (B) is shown enlarged (Bar 200 m). The epidermis (Epi), dermis (Der), subcutaneous tissue (SC), and cutaneous muscle (CM) can be confirmed.
- FIG. 10 is a graph showing the thickness of the skin around the burn wound 3 days after the burn was created.
- FIG. 11 is a graph showing the ratio of the subcutaneous tissue in the entire skin layer around the burn wound 3 days after the burn was created.
- FIG. 12 shows a skin tissue image directly under the burn wound 3 days after burn creation.
- the fired silk body used in the present invention can be obtained by firing a silk material at a relatively low temperature.
- silk material is a generic name for woven fabrics, knitted fabrics, powders, cotton, yarn, etc. These are fired alone or in combination.
- the firing temperature of the silk material is 1400 ° C or lower, more preferably in the temperature range of 500 ° C to 1000 ° C.
- the firing atmosphere is performed in an inert gas atmosphere such as nitrogen gas or argon gas or in a vacuum to prevent the silk material from burning and ashing.
- the firing conditions are such that rapid firing is avoided and the firing is performed in a plurality of stages.
- the temperature of a silk material is increased at a moderate heating rate of 100 ° C./hour, preferably 50 ° C./hour or less in an inert gas atmosphere up to the first firing temperature (for example, 500 ° C.).
- the primary firing is performed for several hours at this primary firing temperature.
- the temperature is raised to a secondary firing temperature (for example, 700 ° C) at a moderate temperature increase rate of 100 ° C or less, preferably 50 ° C or less per hour. It is held for several hours at the secondary firing temperature and then secondary firing is performed.
- it cools by and takes out the target silk sintered body from a baking furnace. Na After the primary firing, it may be continued without cooling to room temperature, that is, may continue to the secondary firing step as it is.
- the firing conditions are not limited to those described above, and can be appropriately changed depending on the type of silk material to be used, the desired function of the fired body, and the like.
- firing is performed in multiple stages, heated at a moderate temperature increase rate, and fired at a low temperature of 1000 ° C.
- rapid degradation of protein higher-order structures in which an amorphous structure and a crystalline structure are complicated is avoided, and various functions are produced particularly when a large amount of nitrogen components remain.
- a soft (flexible) silk fired body with black wrinkles can be obtained without making a graph eye toy.
- Figure 1 shows the Raman spectrum of the fired product when coarse-grained silk is fired at a high temperature of 2000 ° C. Ru It is understood by grayed Rafaitoi spoon from the fact that the peak can be seen at the 1335cm _1.
- FIG. 5 is a Raman spectrum diagram of a fired product when fired with C.
- the firing temperature is 1400 ° C
- the peak value is low, but the peaks at the above three locations are observed.
- a calcination temperature of 1000 ° C. or lower the above-mentioned remarkable peak is not observed, so it is considered that the graph eye toy almost occurred.
- Table 1 shows the results of elemental analysis (semi-quantitative analysis results) using an electron microanalyzer of the fired product obtained by firing a silk knitted silk fabric at 700 ° C in a nitrogen atmosphere.
- Measurement conditions are acceleration voltage: 15 kV, irradiation current: 1 ⁇ , and probe diameter: 100 m.
- the values in the table indicate the tendency of the detected elements and are not guaranteed values. As is clear from Table 1, it can be seen that 27.4 wt% of nitrogen element remains. In addition, it can be seen that other elements derived from amino acids are multi-elements that remain.
- Table 2 Elements CN 0 Na Mg AI Si PS CI K Ca wt% 74.6 15.7 5.1 0.3 0.3 0.1 0.7 0.1 0.2 0.1 2.7
- Table 2 shows the results of elemental analysis (semi-quantitative analysis results) of the fired product obtained by firing a silk knitted silk fabric at 1400 ° C in a nitrogen atmosphere using an electron beam mouth analyzer.
- Measurement conditions are acceleration voltage: 15 kV, irradiation current: 1 ⁇ , and probe diameter: 100 m.
- the values in the table indicate the tendency of the detected elements and are not guaranteed values.
- Table 3 shows the results of elemental analysis (semi-quantitative analysis) of the fired product obtained by firing rabbit non-woven fabric in a nitrogen atmosphere at 700 ° C using an electron beam microanalyzer.
- Measurement conditions are acceleration voltage: 15 kV, irradiation current: 1 ⁇ , and probe diameter: 100 m.
- the values in the table indicate the tendency of the detected elements and are not guaranteed values.
- Fig. 5 is a FE-SEM photograph of silk material fired at 700 ° C. On the surface, there is a thin film that appears to be due to baking residues derived from amino acids such as nitrogen.
- Fig. 6 shows the FE-SEM photo of the silk material fired at a high temperature of 2000 ° C.
- Table 4 shows the antibacterial test results of the fired products obtained by firing the rabbit woven fabric at 700 ° C in a nitrogen atmosphere.
- Standard cotton cloth is used for unprocessed cloth.
- the number of unprocessed cloth bacteria indicates the number of bacteria that have been inoculated and grown on unfired cloth.
- 2.2E + 04 is 2.2 X 10 4 and 4.3 is the logarithm of the value.
- having an antibacterial effect is that, as described above, a large amount of particularly nitrogen elements derived from amino acids remains by baking in multiple stages, a slow heating rate, and preferably low temperature baking at 1400 ° C or lower. It is speculated that it is caused by
- the silk fired body is activated to form pores on the surface to increase the surface area.
- the water absorption is increased, and when used for wounds, moisture, blood, pus, etc. in the wound are appropriately absorbed.
- the antibacterial property is further increased, which is preferable.
- the activation treatment is performed, for example, on the high-temperature steam of about 850 ° C (1000 ° C or less) with the above-mentioned silk fired body This allows the formation of a large number of minute holes (diameter, 0. Inn! To several tens of nm) on the surface of the silk fired body.
- the silk fired body obtained by firing as described above may be irradiated with microwaves (frequency: 2.45 GHz) to form pores on the surface of the silk fired body.
- microwaves frequency: 2.45 GHz
- the silk fired body When used as a wound dressing, can be formed into a woven fabric, knitted fabric or nonwoven fabric and used as it is as a gauze. Or it can be done by using silk fired bodies in the form of threads.
- a silk fired body obtained by firing a silk material at a low temperature as described above is suitable as a wound dressing because it maintains flexibility and has excellent antibacterial properties. In addition, it has excellent water absorption and absorbs and retains moisture, blood, pus, etc. from the wound as appropriate, so the wound can be dried quickly and healing can be accelerated.
- the silk fiber is a fiber bundle in which a number of fiber mouth-in fibers are gathered, and there is a space between the fiber bundles, and the fiber bundle is further formed in a woven fabric or the like.
- the woven fabric itself has a space and has a three-dimensional structure in which many pores are formed on the surface of each carbonized fiber mouth-in fiber. Due to the presence of the space, it has moderate breathability and moisture retention, and it is possible to prevent as much as possible the situation where the regenerating skin is peeled off when the wound force is also peeled off.
- a wound healing agent may be contained in a woven fabric, a knitted fabric, or a nonwoven fabric.
- the wound healing agent usual ones such as iodine and potassium iodide can be used.
- the above-mentioned silk fired body is pulverized into a powder of an appropriate size, and the powder itself is used as a wound covering material, that is, a wound healing agent, and a single wrinkle is used in combination with other wound healing agents. May be. That is, it can also be used as a plaster for adhesive bandages.
- the temperature was increased at a moderate temperature increase rate, and the primary calcination was carried out at this primary calcination temperature for 5 hours.
- the temperature was raised in a nitrogen gas atmosphere to a secondary firing temperature (700 ° C) at a moderate temperature increase rate of about 50 ° C per hour. Secondary calcination was performed by holding at the next calcination temperature for 5 hours. Subsequently, it was cooled to obtain a silk fired body shown in FIG.
- 9cm X 9cm silk fabric was fired at 700 ° C as described above, and this fired silk was sandwiched between unglazed plates and stored in a 500W household microwave oven and irradiated with microwaves for 6 minutes. did.
- mice Examples of animal experiments using mice are shown below.
- the wound area was measured over time after creating a third burn on the back skin of the mouse. Furthermore, since burn wounds are characterized by edema, edema is also considered as an index for evaluating wound healing, and the ratio of the burn wound and the surrounding subcutaneous tissue to the entire skin was used as an index of edema and examined. .
- mice aged 7-10 weeks were used.
- the ointment was applied and photographed in the same manner as immediately after the wound was created. After capturing the images obtained with a digital camera into a computer, the area was measured with Free Software SCION. The ratio (%) of the wound area on each measurement day to the wound area on the wound creation day was obtained, and the difference due to the presence or absence of CS was statistically examined.
- a total of 20 burn wounds were created by placing two tips of the electric iron on the back of 10 mice.
- the wound treatment was divided into two groups of 5 animals and the same wound treatment as in the above experiment was performed.
- Three days after the creation of the burn wound sacrificing was performed under inhalation anesthesia with jetyl ether, and the wound tissue including the tissue around the wound was removed.
- a 4 m-thick paraffin piece was prepared and stained with hematoxylin 'eosin (hereinafter referred to as HE staining) to prepare a tissue specimen with a cross section of the skin. Each specimen was then photographed using an optical microscope to observe the tissue and measure the thickness of the skin and subcutaneous tissue.
- HE staining hematoxylin 'eosin
- the skin thickness is the distance from the epidermis to the dermo-adipous junction, and the distance from the dermo-adipous junction to the skin muscle is the subcutaneous tissue.
- the cross section of the tissue may be cut obliquely, and the skin thickness of the vertical cross section may not be measured. Therefore, in order to increase reliability, we decided to calculate the ratio of the thickness of the subcutaneous tissue in the entire skin.
- the measurement site is one place directly under the burn wound center and three places (Ml, M2, M3) around the burn wound edge at about 500 / zm. Measured as an enclosure. To obtain normal skin data, similar tissue specimens were prepared and evaluated using 3 male mice of the same age.
- FIG. 7A, B A photograph one day after the burn was created and a drawing of the measurement site was shown (Fig. 7A, B).
- the area painted in Figure 7B is the area where the electric iron touched, and the area around it is an edema area.
- the wound area included the range of edema induced after burns. Comparing the wound area ratio (%) on each measurement day to the wound area on the wound creation date (Fig. 8), the CS (+) group showed a significant tendency to reduce the wound area throughout the observation period compared to the CS (-) group. Recognized by In the CS (-) group, the wound area tended to expand from the wound creation area until 3 days after the injury, but the CS (+) group tended to shrink the wound area consistently. It was. This indicates that the CS (+) group is macroscopically edema is mild.
- FIG. 9A and B A weakly enlarged tissue image of the HE-stained skin section (Figs. 9A and B) and a strongly enlarged tissue image around the burn wound (Figs. 9C and D) are shown.
- the subcutaneous tissue around the burn wound was more stained with eosin than in the CS (+) group. This means that the ratio of yarn and tissue gap and vascular 'lymphatic system is high, suggesting that the CS (1) group is more edematous.
- both groups are close to burn wounds around the wound, and compared to normal skin.
- Significantly strong force Compared between the CS (—) group and the cs (+) group no significant difference was observed at any site (Fig. 10).
- the cs (-) group was significantly more powerful than the normal skin even though it was at the measurement site of the deviation.
- the CS (+) group showed no significant difference (Fig. 11).
- the ratio of subcutaneous tissue in the CS (+) group was significantly smaller than that in the CS (-) group.
- CS inflammatory cell migration. It is generally accepted that the wound healing process can be divided into three stages: inflammation, granulation, and remodeling. Since the depth of the burn progresses up to 48 hours after the injury, it is considered that the wound progressed after 3 days after the injury examined in this experiment.
- neutrophils and monocytes are moistened at the site of injury, and damaged cells are phagocytosed and secreted by physiologically active substances such as cytosines.
- Neutrophils play a major role in the inflammation healing process, and are known to disappear early in the third and subsequent days. Poverty ⁇ Decomposition is considered important. The cellular dynamics over time after the creation of a burn wound is an issue that must be studied in the future.
- CS may directly inhibit edema by inhibiting vascular permeability.
- Substances that cause inflammation of various cellular forces in tissues are released by physical or chemical stimuli, resulting in increased permeability of capillary walls and tissue edema.
- Known factors that mediate inflammation include histamine, prazicun, and vascular endothelial growth factor (VEGF).
- Histamine has a vasodilatory action and a capillary permeability enhancing action
- VEGF is a mediator that is said to be involved in vascularization and capillary permeability enhancement.
- Edema is the force that is generated when the fluid that deviates from the capillaries exceeds the lymph flow that drains the tissue in that area.
- CS is considered to have the property of directly suppressing the action of vascular permeable substances such as VEGF.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Textile Engineering (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/596,895 US20080249452A1 (en) | 2004-09-22 | 2005-07-08 | Wound-Covering Material |
JP2006536321A JPWO2006033196A1 (ja) | 2004-09-22 | 2005-07-08 | 創傷被覆材 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004274797 | 2004-09-22 | ||
JP2004-274797 | 2004-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006033196A1 true WO2006033196A1 (ja) | 2006-03-30 |
Family
ID=36089961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/012698 WO2006033196A1 (ja) | 2004-09-22 | 2005-07-08 | 創傷被覆材 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20080249452A1 (ja) |
JP (1) | JPWO2006033196A1 (ja) |
WO (1) | WO2006033196A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012533354A (ja) * | 2009-07-14 | 2012-12-27 | タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ | 創傷治癒のための電界紡糸絹材料システム |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2856873T3 (es) | 2012-02-06 | 2021-09-28 | Childrens Medical Center | Biomaterial multicapa para la regeneración de tejidos y la cicatrización de las heridas |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10155891A (ja) * | 1987-10-06 | 1998-06-16 | Johnson & Johnson Prod Inc | 活性炭含有創傷用包帯 |
JPH1156996A (ja) * | 1997-08-22 | 1999-03-02 | Unitika Ltd | 医療用脱臭被覆材 |
JP2002076686A (ja) * | 2000-08-24 | 2002-03-15 | Shiruensu Kk | 電磁波シールド材の製造方法 |
WO2004009108A1 (en) * | 2002-07-23 | 2004-01-29 | Jong-Hyun Nam | Antipyrotic and method of manufacturing the same |
JP2004024481A (ja) * | 2002-06-25 | 2004-01-29 | Yoichi Kadokami | 抗菌性医用材料 |
JP2005192937A (ja) * | 2004-01-09 | 2005-07-21 | Hinomaru Carbo Techno Co Ltd | 皮膚保護シート |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE342815A (ja) * | 1926-07-08 | |||
JP2005350307A (ja) * | 2004-06-11 | 2005-12-22 | Shinano Kenshi Co Ltd | 改質炭素素材およびその製造方法 |
JP2006083143A (ja) * | 2004-09-17 | 2006-03-30 | Shinano Kenshi Co Ltd | 皮膚外用剤 |
-
2005
- 2005-07-08 JP JP2006536321A patent/JPWO2006033196A1/ja active Pending
- 2005-07-08 US US11/596,895 patent/US20080249452A1/en not_active Abandoned
- 2005-07-08 WO PCT/JP2005/012698 patent/WO2006033196A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10155891A (ja) * | 1987-10-06 | 1998-06-16 | Johnson & Johnson Prod Inc | 活性炭含有創傷用包帯 |
JPH1156996A (ja) * | 1997-08-22 | 1999-03-02 | Unitika Ltd | 医療用脱臭被覆材 |
JP2002076686A (ja) * | 2000-08-24 | 2002-03-15 | Shiruensu Kk | 電磁波シールド材の製造方法 |
JP2004024481A (ja) * | 2002-06-25 | 2004-01-29 | Yoichi Kadokami | 抗菌性医用材料 |
WO2004009108A1 (en) * | 2002-07-23 | 2004-01-29 | Jong-Hyun Nam | Antipyrotic and method of manufacturing the same |
JP2005192937A (ja) * | 2004-01-09 | 2005-07-21 | Hinomaru Carbo Techno Co Ltd | 皮膚保護シート |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012533354A (ja) * | 2009-07-14 | 2012-12-27 | タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ | 創傷治癒のための電界紡糸絹材料システム |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006033196A1 (ja) | 2008-05-15 |
US20080249452A1 (en) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011256404B2 (en) | Reinforced absorbable multi-layered fabric for hemostatic applications | |
Lee et al. | Fabrication and characterization of hydrocolloid dressing with silk fibroin nanoparticles for wound healing | |
EP3220970B1 (en) | Fenestration kits for making fenestrated placental tissue allografts and methods of using the same | |
Danylchenko et al. | Chitosan–hydroxyapatite composite biomaterials made by a one step co-precipitation method: preparation, characterization and in vivo tests | |
AU2020267589B2 (en) | Tissue derived porous matrices and methods for making and using same | |
Arasteh et al. | Efficient wound healing using a synthetic nanofibrous bilayer skin substitute in murine model | |
Lei et al. | Preparation of ADM/PRP freeze-dried dressing and effect of mice full-thickness skin defect model | |
Hu et al. | Multifunctional hydrogel based on dopamine-modified hyaluronic acid, gelatin and silver nanoparticles for promoting abdominal wall defect repair | |
KR101404089B1 (ko) | 양막 추출물을 함유하는 이중층 하이드로겔 습윤드레싱 및 그 제조방법 | |
Lee et al. | The histopathologic features of Integra® Dermal Regeneration Template. | |
Panayi et al. | Novel application of autologous micrografts in a collagen-glycosaminoglycan scaffold for diabetic wound healing | |
WO2006033196A1 (ja) | 創傷被覆材 | |
Mensik et al. | Effectiveness and safety of the PEGT/PBT copolymer scaffold as dermal substitute in scar reconstruction wounds (feasibility trial) | |
Lee et al. | Effectiveness of woven silk dressing materials on full-skin thickness burn wounds in rat model | |
EP3365036B1 (en) | Vascular patch using silk matrix and method of manufacturing the same | |
CN115554467A (zh) | 一种颅骨修复材料及其制备方法 | |
Guan et al. | In vivo biodegradation of porous silk fibroin films implanted beneath the skin and muscle of the rat | |
JP2021020868A (ja) | 熱傷用修復材 | |
US20230310706A1 (en) | Burn restoration material | |
CN110585486A (zh) | 羊膜复合材料及其制备方法和应用 | |
JP2005350307A (ja) | 改質炭素素材およびその製造方法 | |
US20230347015A1 (en) | Lyophilized perforated placental membrane tissue grafts | |
CN107469129A (zh) | 一种抗菌敷料及其制备方法 | |
JP2023184057A (ja) | 熱傷治療用の細胞及び熱傷治療方法 | |
CN116490225A (zh) | 耳廓皮肤缺损部的植皮填补/缓冲构件 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006536321 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11596895 Country of ref document: US |